Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M L Rutllant

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Sangre|January 1, 1984
[Obtaining plasma derivatives for coagulation versus new non-human sources for obtaining factors]M L Rutllant
Sangre|January 1, 1978
[Role of chromogenic substrates in the study of blood coagulation and fibrinolysis]M L Rutllant
Sangre|January 1, 1985
[Inhibitors of coagulation and of fibrinolysis]M L Rutllant
Sangre|January 1, 1978
[Experiences with the glycerol erythrocyte lysis test (author's transl)]E Gimferrer, M Baiget, M L Rutllant
Sangre|January 1, 1978
[Experiences in the assessment of haemoglobin A2 by microchromatography in DEAE cellulose (author's transl)]M Baiget, E Gimferrer, M L Rutllant
Intensive Care Medicine|January 1, 1993
New biological concepts on coagulation inhibitorsN Sala, J Fontcuberta, M L Rutllant
Sangre|January 1, 1973
[Congenital factor XIII deficiency]M L Rutllant, E Gimferrer, J Viñas
Sangre|January 1, 1979
[Polymerization of human and bovine fibrinogen: a comparative study (author's transl)]J Felez, M Borrell, J Fontcuberta, et al.
Lancet (London, England)|January 11, 1975
Letter: Differentiation of iron deficiency from thalassaemia traitE Gimferrer, G Marigo, M L Rutllant, et al.
Thrombosis Research|July 1, 1988
Quantitative and qualitative congenital deficiency of antithrombin III: a new molecular variant called ATIII-Barcelona 2J Fontcuberta, E Grau, N Rubio, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Sangre|January 1, 1984
[Obtaining plasma derivatives for coagulation versus new non-human sources for obtaining factors]M L Rutllant
Sangre|January 1, 1978
[Role of chromogenic substrates in the study of blood coagulation and fibrinolysis]M L Rutllant
Sangre|January 1, 1985
[Inhibitors of coagulation and of fibrinolysis]M L Rutllant
Sangre|January 1, 1978
[Experiences with the glycerol erythrocyte lysis test (author's transl)]E Gimferrer, M Baiget, M L Rutllant
Sangre|January 1, 1978
[Experiences in the assessment of haemoglobin A2 by microchromatography in DEAE cellulose (author's transl)]M Baiget, E Gimferrer, M L Rutllant
Intensive Care Medicine|January 1, 1993
New biological concepts on coagulation inhibitorsN Sala, J Fontcuberta, M L Rutllant
Sangre|January 1, 1973
[Congenital factor XIII deficiency]M L Rutllant, E Gimferrer, J Viñas
Sangre|January 1, 1979
[Polymerization of human and bovine fibrinogen: a comparative study (author's transl)]J Felez, M Borrell, J Fontcuberta, et al.
Lancet (London, England)|January 11, 1975
Letter: Differentiation of iron deficiency from thalassaemia traitE Gimferrer, G Marigo, M L Rutllant, et al.
Thrombosis Research|July 1, 1988
Quantitative and qualitative congenital deficiency of antithrombin III: a new molecular variant called ATIII-Barcelona 2J Fontcuberta, E Grau, N Rubio, et al.
Pageof 3